[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
Journal Information::
Editorial Board::
Executive Members::
Instruction to Authors::
Peer Review::
Articles Archive::
Indexing Databases::
Contact Us::
Site Facilities::
::
Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
:: Volume 10, Issue 3 (10-2008) ::
J Gorgan Univ Med Sci 2008, 10(3): 19-26 Back to browse issues page
Conventional chemoradiation with Cisplatin Versus hemoradiation with Cisplatin plus Gemcitabine in uterine cervical cancer
Ahmad Ameri (MD) , Morteza Tabatabaeefar (MD) , Seyyed Reza Khandoozi (MD) * 1, Ehsan Hatami (MD) , Khosrow Mojirshaybani (MD) , Asadollah Alidoosti (MD)
Abstract:   (24884 Views)
Background and Objective: Due to high mortality and morbidity of the cervical cancer we decided to compare benefits and advers effects of Gemcitabine plus conventional chemoradiation with conventional chemoradiation with cisplatin alone in Imam Hossein hospital, in Tehran, Iran. Materials and Methods: This double blind clinical trial, was carried out on 34 patients with documented cervical carcinoma during 2006-07 the patients divided into two sub groups: (A)Conventional concurrent chemoradiation with cisplatin(N=18) versus(B) concurrent chemoradiation with cisplatin plus gemicitabine (N=16). The patients with clinical stage of IB2-IVA and normal cell blood count with normal renal and liver function tests included in the study. Irradiation was delivered to all patients through external and internal beams with same dose and schedule. The patients followed for 3 months at least. Clinical response rate and adverse events included Neutropenin, Thrombocytopenia, anemia, diarrhea, nausea, and vomiting compared in two groups with fisher exact test, and t-test. Results: Despite increasing of complete response rate with adding gemcitabine to conventional treatment(81.2% vs. 66.7%), the difference in two groups was not statistically significant. Conclusion: This study indicated that the addition of gemicatabine to conventional chemoradiation with cisplatinrevealed no significant benefits. All adverse events in combination chemotherapy group were greater than conventional treatment.
Keywords: Cervical cancer, Chemoradiation, Cisplatin, Gemcitabine
Full-Text [PDF 285 kb] [English Abstract]   (18265 Downloads)    
Type of Study: Original Articles | Subject: General
* Corresponding Author Address: dr92002@yahoo.com


XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Ahmad Ameri (MD), Morteza Tabatabaeefar (MD), Seyyed Reza Khandoozi (MD), Ehsan Hatami (MD), Khosrow Mojirshaybani (MD), Asadollah Alidoosti (MD). Conventional chemoradiation with Cisplatin Versus hemoradiation with Cisplatin plus Gemcitabine in uterine cervical cancer. J Gorgan Univ Med Sci 2008; 10 (3) :19-26
URL: http://goums.ac.ir/journal/article-1-388-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 10, Issue 3 (10-2008) Back to browse issues page
مجله دانشگاه علوم پزشکی گرگان Journal of Gorgan University of Medical Sciences
Persian site map - English site map - Created in 0.05 seconds with 35 queries by YEKTAWEB 4660
Creative Commons License
This work is licensed under a Creative Commons — Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)